These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.
This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.
- RDBPC three month study [Fonseca, B., et al. (2015). Neurology. Conference: 67th American Academy of Neurology Annual Meeting, AAN, 84.] evaluated healthy men and women between the ages of 50 to 70 with age-associated memory impairment. The study showed significant differences between active and placebo groups on improvements in working memory and ease of falling asleep. Claims based on 900 mg Neumentix containing 14.5% - 17.5% Rosmarinic Acid and 24.0 - 32.0% Phenolics (expressed as gallic acid equivalents) taken once daily for 12 weeks.